---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335106"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-08-05T20:10:20+00:00"
generated_at: "2026-08-05T20:13:12.826457+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q2 revenue $20.1M, down 7.6% YoY; adjusted EBITDA improves 84%

## Summary
- Revenue $20.1M, down 7.6% YoY; consumables $9.4M (-10%), instruments $5.1M (-2%), services $5.6M (-8%).
- Net loss from continuing ops $21.5M vs $17.7M; operating loss $25.4M vs $25.7M.
- Adjusted EBITDA loss $2.5M, improvement of $13.6M or 84% YoY.
- Merger with Treeline Biosciences progressing; stockholder vote expected before year-end 2026.
- Withdrew full year 2026 revenue outlook due to pending merger.

## SEC filing metadata
- accession: 0001193125-26-335106
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-08-05T20:10:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/0001193125-26-335106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/lab-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335106
- JSON: https://secwatch.observer/filing/0001193125-26-335106.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.